Literature DB >> 28548675

Inducible Bcl-2 gene RNA interference mediated by aptamer-integrated HDV ribozyme switch.

Yuanyuan Zhang1, Jine Wang2, Hui Cheng2, Na Sun2, Min Liu2, Zhengyan Wu3, Renjun Pei2.   

Abstract

The regulation of RNA interference (RNAi) could be a powerful method for the study of temporal and dose dependent effects of gene expression. In this study, we designed the hepatitis delta virus (HDV) ribozyme with an embedded theophylline aptamer as the sensor domain and the pri-miRNA of endogenous gene Bcl-2 as the effector domain to engineer an RNAi-regulatory device in MCF-7 cells. The system allowed us to control gene expression by adding theophylline into the culture media in a dose dependent fashion. This is the pioneering application of ribozyme switches to activate RNAi for modulating endogenous genes in mammalian cells. The platform sets the stage for investigations of other endogenous genes that regulate various biological functions such as differentiation, cell division or cell death, and provides a promising interface with other universal RNAi-based decision-making circuits that operate in mammalian cells. It can be used to study more genes associated with cancer and screen for potential drug targets for gene therapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28548675     DOI: 10.1039/c7ib00029d

Source DB:  PubMed          Journal:  Integr Biol (Camb)        ISSN: 1757-9694            Impact factor:   2.192


  3 in total

Review 1.  Aptamer-based and aptazyme-based riboswitches in mammalian cells.

Authors:  Yohei Yokobayashi
Journal:  Curr Opin Chem Biol       Date:  2019-06-22       Impact factor: 8.822

Review 2.  Aptamers in Virology-A Consolidated Review of the Most Recent Advancements in Diagnosis and Therapy.

Authors:  Tejabhiram Yadavalli; Ipsita Volety; Deepak Shukla
Journal:  Pharmaceutics       Date:  2021-10-09       Impact factor: 6.321

Review 3.  The role of small molecules in cell and gene therapy.

Authors:  Lewis L Brayshaw; Carlos Martinez-Fleites; Takis Athanasopoulos; Thomas Southgate; Laurent Jespers; Christopher Herring
Journal:  RSC Med Chem       Date:  2020-12-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.